Wen Gao1, Lingxiang Liu2, Jing Xu2, Qianwen Shao2, Yiqian Liu2, Huazong Zeng3, Yongqian Shu4. 1. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. Electronic address: yoghurt831030@126.com. 2. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. 3. Shanghai Sensichip Info tech Co Ltd., Shanghai 200433, China. 4. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. Electronic address: shuyongqian@csco.org.cn.
Abstract
INTRODUCTION: Recent studies have shown that miR-31 could play a potential role as diagnostic and prognostic biomarkers of several cancers including lung cancer. The aim of this study is to globally summarize the predicting targets of miR-31 and their potential function, pathways and networks, which are involved in the biological behavior of lung cancer. METHODS: We have conducted the natural language processing (NLP) analysis to identify lung cancer-related molecules in our previous work. In this study, miR-31 targets predicted by combinational computational methods. All target genes were characterized by gene ontology (GO), pathway and network analysis. In addition, miR-31 targets analysis were integrated with the results from NLP analysis, followed by hub genes interaction analysis. RESULT: We identified 27 hub genes by the final integrative analysis and suggested that miR-31 may be involved in the initiation, progression and treatment response of lung cancer through cell cycle, cytochrome P450 pathway, metabolic pathways, apoptosis, chemokine signaling pathway, MAPK signaling pathway, as well as others. CONCLUSION: Our data may help researchers to predict the molecular mechanisms of miR-31 in the molecular mechanism of lung cancer comprehensively. Moreover, the present data indicate that the interaction of miR-31 targets may be promising candidates as biomarkers for the diagnosis, prognosis and personalized therapy of lung cancer.
INTRODUCTION: Recent studies have shown that miR-31 could play a potential role as diagnostic and prognostic biomarkers of several cancers including lung cancer. The aim of this study is to globally summarize the predicting targets of miR-31 and their potential function, pathways and networks, which are involved in the biological behavior of lung cancer. METHODS: We have conducted the natural language processing (NLP) analysis to identify lung cancer-related molecules in our previous work. In this study, miR-31 targets predicted by combinational computational methods. All target genes were characterized by gene ontology (GO), pathway and network analysis. In addition, miR-31 targets analysis were integrated with the results from NLP analysis, followed by hub genes interaction analysis. RESULT: We identified 27 hub genes by the final integrative analysis and suggested that miR-31 may be involved in the initiation, progression and treatment response of lung cancer through cell cycle, cytochrome P450 pathway, metabolic pathways, apoptosis, chemokine signaling pathway, MAPK signaling pathway, as well as others. CONCLUSION: Our data may help researchers to predict the molecular mechanisms of miR-31 in the molecular mechanism of lung cancer comprehensively. Moreover, the present data indicate that the interaction of miR-31 targets may be promising candidates as biomarkers for the diagnosis, prognosis and personalized therapy of lung cancer.
Authors: Benjamin P Keith; Jasmine B Barrow; Takahiko Toyonaga; Nevzat Kazgan; Michelle Hoffner O'Connor; Neil D Shah; Matthew S Schaner; Elisabeth A Wolber; Omar K Trad; Greg R Gipson; Wendy A Pitman; Matthew Kanke; Shruti J Saxena; Nicole Chaumont; Timothy S Sadiq; Mark J Koruda; Paul A Cotney; Nancy Allbritton; Dimitri G Trembath; Francisco Sylvester; Terrence S Furey; Praveen Sethupathy; Shehzad Z Sheikh Journal: JCI Insight Date: 2018-10-04
Authors: Sandra Gallach; Eloisa Jantus-Lewintre; Silvia Calabuig-Fariñas; David Montaner; Sergio Alonso; Rafael Sirera; Ana Blasco; Marta Usó; Ricardo Guijarro; Miguel Martorell; Carlos Camps Journal: Oncotarget Date: 2017-06-22
Authors: Lotte Pyfferoen; Elisabeth Brabants; Celine Everaert; Nancy De Cabooter; Kelly Heyns; Kim Deswarte; Manon Vanheerswynghels; Sofie De Prijck; Glenn Waegemans; Melissa Dullaers; Hamida Hammad; Olivier De Wever; Pieter Mestdagh; Jo Vandesompele; Bart N Lambrecht; Karim Y Vermaelen Journal: Oncoimmunology Date: 2016-11-08 Impact factor: 8.110